权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

suPAR and renal fibrosis

suPAR与肾纤维化

基本信息

批准号：
10220027
负责人：
Jochen Reiser
金额：
$ 45.04万
依托单位：
RUSH UNIVERSITY MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-07-20 至 2025-04-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10220027
关键词：
Affect Affinity Animal Model Binding Proteins Biological Assay Blood Bone Marrow CD44 gene CRISPR/Cas technology Cell physiology Cells Cellular Structures Chronic Kidney Failure Clinical Cultured Cells Development Disease Disease Progression Epithelial Cells Event Exhibits Family Fibrosis Fingers Focal Segmental Glomerulosclerosis Grant HK2 gene Health Healthcare In Vitro Incidence Individual Infusion procedures Injury Innate Immune Response Integrin alphaV Integrin alphaVbeta3 Integrin beta Chains Integrins Kidney Kidney Diseases Kidney Failure Knock-out Knockout Mice Measures Mediating Medical Modality Modeling Molecular Myeloid Cells Nephrons Neurotoxins Participant Pathway interactions Patients Pattern Peptides Plasma Play Prevention strategy Protein Isoforms Proteins Publishing Recurrence Reporting Risk Factors Role Signal Transduction Signaling Protein Stream Surface Plasmon Resonance TGFBI gene Testing Therapeutic Time Toxin Transgenic Mice Translating Tubular formation United States Ureteral obstruction Urokinase Plasminogen Activator Receptor base cell injury cohort combat effective therapy experimental study glomerulosclerosis in vivo injured insight integrin beta6 interstitial kidney fibrosis member mortality mouse model novel novel therapeutics overexpression periostin podocyte post-transplant prevent programs protein protein interaction treatment strategy

项目摘要

Abstract Chronic kidney disease (CKD) is a major driver of mortality and a financial challenge for healthcare in the United States. Treatment options are scarce, indirect and not sufficient, whilst CKD is growing into one of the largest unmet medical needs of our time. Once the kidney is injured, progression of the disease is dependent on the degree of fibrosis, which can differ from patient to patient. We and others have made the unique observation that the soluble form of urokinase plasminogen activator receptor (uPAR) is a risk factor for incident and prevalent kidney diseases across the spectrum of CKD. suPAR is a three finger toxin that is produced by immature myeloid cells in the bone marrow and circulates in the plasma to regulate integrin function in the kidney. Elevated suPAR levels or the presence of certain suPAR isoforms are causally involved in CKD by mediating injury to both glomerular podocytes and proximal tubular cells through specific interactions with β integrins. Building on our published and novel preliminary observations that suPAR-mediated integrin activation drives fibrotic programs in the kidney, we plan to investigate the consequences of suPAR interactions with distinct β integrins in different nephron segments and explore its role in promoting both glomerular and tubulointerstitial fibrosis. Three independent aims are being proposed: First, we will determine the molecular mechanisms that translate suPAR-αvβ3 integrin signaling into podocyte injuries and glomerular sclerosis using surface plasmon resonance assays, cultured cell experiments and suPAR transgenic mouse models. Second, we will determine the molecular mechanisms that drive suPAR-αvβ6 integrin signaling in tubular injuries and tubulointerstitial fibrosis by genetically modifying the tubular integrin function. Third, we will investigate therapeutic modalities using peptide based blocking strategies for uPAR and its associated fibrotic pathways. Experiments outlined in this proposal will allow us to separate different steps in the suPAR cascade of kidney fibrosis and define best options to intervene. As such, insights from this grant will provide a basis for preventive and treatment strategies to combat suPAR mediated fibrosis and CKD.

摘要